SE429404B - Forfarande for framstellning av en vattenloslig, makromolekyler produkt, anvendbar som syretransporterande material i ett blodersettningsmedel - Google Patents

Forfarande for framstellning av en vattenloslig, makromolekyler produkt, anvendbar som syretransporterande material i ett blodersettningsmedel

Info

Publication number
SE429404B
SE429404B SE7611797A SE7611797A SE429404B SE 429404 B SE429404 B SE 429404B SE 7611797 A SE7611797 A SE 7611797A SE 7611797 A SE7611797 A SE 7611797A SE 429404 B SE429404 B SE 429404B
Authority
SE
Sweden
Prior art keywords
substancer
blood
soluble
preparing
procedure
Prior art date
Application number
SE7611797A
Other languages
English (en)
Other versions
SE7611797L (sv
Inventor
Jeffrey Tze-Fei Wong
Original Assignee
Hematech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hematech Inc filed Critical Hematech Inc
Publication of SE7611797L publication Critical patent/SE7611797L/sv
Publication of SE429404B publication Critical patent/SE429404B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/102499—Blood gas standard or control
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/104998—Glucose, ketone, nitrate standard or control
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/105831—Protein or peptide standard or control [e.g., hemoglobin, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/108331—Preservative, buffer, anticoagulant or diluent

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Peptides Or Proteins (AREA)
SE7611797A 1975-10-22 1976-10-22 Forfarande for framstellning av en vattenloslig, makromolekyler produkt, anvendbar som syretransporterande material i ett blodersettningsmedel SE429404B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA238,305A CA1055932A (en) 1975-10-22 1975-10-22 Blood substitute based on hemoglobin

Publications (2)

Publication Number Publication Date
SE7611797L SE7611797L (sv) 1977-04-23
SE429404B true SE429404B (sv) 1983-09-05

Family

ID=4104351

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7611797A SE429404B (sv) 1975-10-22 1976-10-22 Forfarande for framstellning av en vattenloslig, makromolekyler produkt, anvendbar som syretransporterande material i ett blodersettningsmedel

Country Status (11)

Country Link
US (1) US4064118A (sv)
JP (1) JPS6021124B2 (sv)
AU (1) AU510466B2 (sv)
BE (1) BE847462A (sv)
CA (1) CA1055932A (sv)
DE (1) DE2646854A1 (sv)
FR (1) FR2328478A1 (sv)
GB (1) GB1549246A (sv)
IL (1) IL50697A (sv)
NL (1) NL185131C (sv)
SE (1) SE429404B (sv)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5716815A (en) * 1980-07-02 1982-01-28 Ajinomoto Co Inc Oxygen transporting agent for artificial blood
DE3029307A1 (de) * 1980-08-01 1982-03-04 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Haemoglobin enthaltendes blutersatzmittel
US4427416A (en) 1980-10-10 1984-01-24 Duke University Processes for extracting oxygen from fluids using immobilized hemoglobin
US4343715A (en) * 1980-10-10 1982-08-10 Duke University Immobilized hemoglobin, and processes for extracting oxygen from fluids using the same
US4401652A (en) * 1980-12-31 1983-08-30 Allied Corporation Process for the preparation of stroma-free hemoglobin solutions
JPS5899420A (ja) * 1981-12-04 1983-06-13 Ajinomoto Co Inc 人工血液用酸素運搬剤
DE3320752A1 (de) * 1983-06-09 1984-12-13 Wolfgang Prof. Dr.Dr. 6500 Mainz Barnikol Lumineszierende schichten zur verwendung in vorrichtungen zur bestimmung der sauerstoffkonzentration in gasen und dergleichen durch messung der lumineszensverringerung
GB8328917D0 (en) * 1983-10-28 1983-11-30 Fisons Plc Blood substitute
DE3501349A1 (de) * 1985-01-17 1986-07-17 Battelle-Institut E.V., 6000 Frankfurt Blutersatz
US4584130A (en) * 1985-03-29 1986-04-22 University Of Maryland Intramolecularly cross-linked hemoglobin and method of preparation
FR2600894B1 (fr) * 1986-07-02 1989-01-13 Centre Nat Rech Scient Conjugues macromoleculaires d'hemoglobine, leur procede de preparation et leurs applications
DE3636590A1 (de) * 1986-10-28 1988-05-26 Braun Melsungen Ag Blutersatzmittel
US5753616A (en) * 1986-11-10 1998-05-19 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
US5955581A (en) * 1986-11-10 1999-09-21 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
GB8712240D0 (en) * 1987-05-23 1987-07-01 Fisons Plc Pharmaceutical formulation
FR2630329B1 (fr) * 1988-04-20 1991-07-05 Merieux Inst Conjugues macromoleculaires d'hemoglobine, leur procede de preparation et leurs applications
US5045446A (en) * 1988-08-26 1991-09-03 Cryopharm Corporation Lyophilization of cells
IL90188A0 (en) * 1988-05-18 1989-12-15 Cryopharm Corp Process and medium for the lyophilization of erythrocytes
US5055259A (en) * 1988-07-29 1991-10-08 Sanraku Incorporated Bloodless blood typing training kit
US6187744B1 (en) 1992-03-11 2001-02-13 Michael W. Rooney Methods and compositions for regulating the intravascular flow and oxygenating activity of hemoglobin in a human or animal subject
US5783214A (en) * 1994-06-13 1998-07-21 Buford Biomedical, Inc. Bio-erodible matrix for the controlled release of medicinals
US5888822A (en) * 1995-10-04 1999-03-30 Hycor Biomedical Inc. Erythrocyte sedimentation rate control
US5981507A (en) * 1995-12-14 1999-11-09 Advanced Magnetics, Inc. Polymeric carriers linked to nucleotide analogues via a phosphoramide bond
DE19628705A1 (de) * 1996-07-08 1998-01-15 Fresenius Ag Neue Sauerstoff-Transport-Mittel, diese enthaltende Hämoglobin-Hydroxyethylstärke-Konjugate, Verfahren zu deren Herstellung, sowie deren Verwendung als Blutersatzstoffe
US5895760A (en) 1997-02-04 1999-04-20 Hycor Biomedical, Inc. Erythrocyte sedimentation rate control
AU735799C (en) * 1997-02-28 2005-04-28 Regents Of The University Of California, The Methods and compositions for optimisation of oxygen transport by cell-free systems
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
US6159682A (en) * 1999-04-30 2000-12-12 Streck Laboratories, Inc. Blood control and system for erythrocyte sedimentation measurement
US6124089A (en) * 1999-04-30 2000-09-26 Streck Laboratories, Inc. Blood control and system for erythrocyte sedimentation measurement
US6531321B1 (en) 2000-09-15 2003-03-11 Streck Laboratories, Inc. Blood control and system for erythrocyte sedimentation measurement
CA2319966A1 (en) * 2000-09-19 2002-03-19 Dextro-Sang Corporation Improved dextran-hemoglobin conjugate as potential blood substitute
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
DE10155781A1 (de) * 2001-11-14 2003-05-22 Deutsches Textilforschzentrum Verfahren zur Herstellung von reaktiven Cyclodextrinen, ein damit ausgerüstetes textiles Material und deren Verwendung
US20050164915A1 (en) 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US7271145B2 (en) * 2002-01-11 2007-09-18 Sangart, Inc. Methods and compositions for oxygen transport comprising modified hemoglobin in plasma
US20030153491A1 (en) * 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
DE10209821A1 (de) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10209822A1 (de) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
JP3912206B2 (ja) * 2002-07-05 2007-05-09 株式会社日立製作所 筒内直接燃料噴射装置用燃料ポンプ
DE10237442B4 (de) * 2002-08-16 2004-08-19 Fresenius Kabi Deutschland Gmbh Hochverzweigte, niedrig substituierte Stärkeprodukte
DE10242076A1 (de) * 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh HAS-Allergen-Konjugate
EP1681303B1 (en) 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
RU2329274C2 (ru) * 2002-09-11 2008-07-20 Фрезениус Каби Дойчланд Гмбх Способ получения производных гидроксиалкилкрахмала
ES2314238T3 (es) * 2002-10-08 2009-03-16 Fresenius Kabi Deutschland Gmbh Conjugados de oligosacaridos farmaceuticamente activos.
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
BRPI0412671A (pt) * 2003-08-08 2006-10-03 Fresenius Kabi De Gmbh conjugados de um polìmero e uma proteìna ligados por um grupo de ligação de oxima
US8754031B2 (en) 2004-03-08 2014-06-17 Oncolix, Inc. Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
TWI417303B (zh) 2004-03-11 2013-12-01 Fresenius Kabi De Gmbh 經由還原胺化作用製得之羥烷基澱粉及蛋白質的接合物
TW200603818A (en) * 2004-03-11 2006-02-01 Fresenius Kabi De Gmbh Conjugates of hydroxyethyl starch and erythropoietin
MX2007005640A (es) * 2004-11-10 2007-08-14 Aplagen Gmbh Moleculas que promueven la hematopoyesis.
US7589063B2 (en) * 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
JP2008546732A (ja) * 2005-06-23 2008-12-25 アプラゲン ゲーエムベーハー 多価化合物
EP1762250A1 (en) * 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
CN101528263B (zh) 2006-06-30 2013-01-23 Sku资产管理有限公司 用于癌症的先天性免疫方法的缀合物
CN101199856B (zh) * 2006-12-15 2011-04-20 天津协和生物科技发展有限公司 一种携氧抗休克药物
EP2070951A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Method for producing a hydroxyalkyl starch derivatives with two linkers
EP2070950A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
EP2095829A1 (en) 2008-02-27 2009-09-02 LEK Pharmaceuticals D.D. Selenium containing modifying agents and conjugates
CA2753804C (en) 2009-02-26 2018-03-13 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
US8648046B2 (en) 2009-02-26 2014-02-11 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
WO2011098095A1 (en) 2010-02-09 2011-08-18 Aplagen Gmbh Peptides binding the tpo receptor
GB201609083D0 (en) 2016-05-24 2016-07-06 Syntab Therapeutics Gmbh Synthetic compound
CN114617957B (zh) * 2022-03-10 2024-01-16 中国人民解放军军事科学院军事医学研究院 羟乙基淀粉血红蛋白偶联物及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB736354A (en) 1952-01-28 1955-09-07 Boehringer & Soehne Gmbh Process for the production of preparation suitable as a blood plasma substitute
GB1126628A (en) 1966-06-18 1968-09-11 Bayer Ag Blood volume replacement medium
US3925344A (en) * 1973-04-11 1975-12-09 Community Blood Council Plasma protein substitute
US4001401A (en) * 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
US4001200A (en) * 1975-02-27 1977-01-04 Alza Corporation Novel polymerized, cross-linked, stromal-free hemoglobin

Also Published As

Publication number Publication date
NL7611580A (nl) 1977-04-26
NL185131C (nl) 1990-02-01
DE2646854A1 (de) 1977-05-05
BE847462A (fr) 1977-02-14
JPS6021124B2 (ja) 1985-05-25
AU1885276A (en) 1978-04-27
FR2328478B1 (sv) 1979-03-02
DE2646854C2 (sv) 1989-05-03
NL185131B (nl) 1989-09-01
IL50697A0 (en) 1976-12-31
SE7611797L (sv) 1977-04-23
GB1549246A (en) 1979-08-01
US4064118A (en) 1977-12-20
IL50697A (en) 1979-10-31
FR2328478A1 (fr) 1977-05-20
JPS5251016A (en) 1977-04-23
AU510466B2 (en) 1980-06-26
CA1055932A (en) 1979-06-05

Similar Documents

Publication Publication Date Title
SE429404B (sv) Forfarande for framstellning av en vattenloslig, makromolekyler produkt, anvendbar som syretransporterande material i ett blodersettningsmedel
SE405379B (sv) Produkt, avsedd att anvendas i en automatisk torkmaskin innehallande en frasbildande komponent
NL179051C (nl) Werkwijze ter bereiding van een geneesmiddel met een cardiovasculaire werking, gevormd geneesmiddel en werkwijze ter bereiding van daarvoor geschikte fenoxypropanolaminederivaten.
NL7603881A (nl) Werkwijze ter bereiding van een geneesmiddel, zo gevormd geneesmiddel en werkwijze ter bereiding van daartoe geschikte geneeskrachtige verbindin- gen.
SE7602317L (sv) 1,4-dihydropyridinkarbonsyraalkylestrar till anvendning som lekemedel och sett att framstella desamma
NO146698C (no) Fremgangsmaate for fremstilling av et stabilt langtidsvirkende insulinprodukt.
NL7602443A (nl) Werkwijze voor het bereiden van een metaal-sulfa- diazine, werkwijze voor het bereiden van een ge- neesmiddel dat deze verbinding bevat en gevormd geneesmiddel, verkregen volgens deze werkwijze.
NL7601455A (nl) Werkwijze ter bereiding van prostaglandine-analo- ga; werkwijze ter bereiding van farmaceutische preparaten, alsmede gevormde voortbrengselen.
NL184558C (nl) Werkwijze voor het bereiden van een farmaceutisch preparaat, dat een moederkoornalkaloide bevat; farmaceutisch voorwerp.
NL7505606A (nl) Werkwijze voor het bereiden van 3-amino-fenyl- azijnzuur-derivaten, werkwijze voor het bereiden van herbicide preparaten alsmede aldus verkregen gevormde preparaten.
NL7611660A (nl) Werkwijze voor de bereiding van nieuwe analogen van in de natuur voorkomende prostaglandinen, werkwijze voor de bereiding van daarbij gebruikte tussenprodukten, werkwijze voor de bereiding van een farmaceutisch preparaat dat de bereide nieuwe analogen bevat, alsmede gevormd farmaceu- tisch preparaat verkregen volgens deze werkwijze.
NL7415414A (nl) Hydratropazuurderivaten en werkwijze voor de bereiding daarvan.
NL7416806A (nl) Werkwijze ter bereiding van een geneesmiddel met luteolytische werkzaamheid, alsmede werkwijze ter bereiding van nieuwe prostaanzuurderivaten.
SE7509345L (sv) Pyrimidinyltionofosfonsyraestrar till anvendning som insekticider, akaricider och nematocider och sett for deras framstellning.
NL7608398A (nl) Werkwijze ter bereiding van een farmaceutisch preparaat, gevormd farmaceutisch preparaat, alsmede werkwijze ter bereiding van nieuwe aminobenzocyclohepteenverbindingen en van hun zouten.
NL7508295A (nl) Werkwijze ter bereiding van nieuwe prostaan- zuurderivaten, nieuwe prostaanzuurderivaten alsmede werkwijze ter bereiding van een genees- middel met prostaglandine-werking.
ATA36074A (de) Verfahren zur herstellung von stabilen, trockenenm freifliessenden vitamin b12-praparaten
NL7609935A (nl) Werkwijze ter bereiding van een farmaceutisch preparaat.
NL7603508A (nl) Werkwijze ter bereiding van een geneesmiddel, zo gevormd geneesmiddel en werkwijze ter bereiding van daartoe geschikte geneeskrachtige verbindin- gen.
NL7608538A (nl) Werkwijze voor het bereiden van diaminoandros- taan-derivaten, zuuradditiezouten en quater- naire zouten daarvan, alsmede werkwijze voor het bereiden van een geneesmiddel met neuro- -musculair-blokkerende werking.
NL7600447A (nl) Kaasprodukt, dat een gedeeltelijk oplosbaar, ge- modificeerd, vast weiprodukt bevat.
SE423176B (sv) Forfarande for framstellning av en for foderblandningar avsedd, sparmetaller innehallande produkt
NL7707420A (nl) Werkwijze ter bereiding van een haar-herstel- lend produkt.
NL7504435A (nl) Werkwijze ter bereiding van een geneesmiddel, zo gevormd geneesmiddel en werkwijze ter bereiding van daartoe geschikte actieve verbindingen.
NL7609598A (nl) Werkwijze ter bereiding van een geneesmiddel, zo gevormd geneesmiddel en werkwijze ter be- reiding van daarvoor geschikte geneeskrachtige verbindingen.

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 7611797-7

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 7611797-7

Format of ref document f/p: F